Online citations, reference lists, and bibliographies.

Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy In Peritoneal Carcinomatosis From Ovarian Cancer

P. Piso, M. Dahlke, M. Loss, H. Schlitt
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundIn selected patients with peritoneal carcinomatosis from ovarian cancer prognosis can be improved by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).MethodsBetween September 1995 and February 1999, 19 patients (mean age 52 years, range 30–72 years) with peritoneal carcinomatosis from primary or recurrent epithelial ovarian carcinoma were operated with the aim of complete macroscopical cytoreduction. Surgery was followed by intraoperative HIPEC. The data was analyzed retrospectively.ResultsEleven patients had recurrent and 8 primary ovarian cancer. The median progression free interval was 18 months (range 6–36 months). Macroscopically complete cytoreduction was achieved in 9 patients. Cisplatin (n = 16) or mitoxantrone (n = 3) were used for the intraoperative chemotherapy. The median intraabdominal inflow temperature was 41.5°C. Complications occurred in seven patients. Most frequent complications were anastomotic leakage (2/19) and intraabdominal abscess formation (2/19). One patient died postoperatively. The mean (± SD) overall survival time was 33(± 6) months with a 5-year survival rate of 15%. The survival was found to be influenced by the completeness of cytoreduction (44 ± 11 vs. 25 ± 6 months, p = 0.40), tumor volume (54 ± 10 versus 16 ± 4, p = 0.002) and presence of lymph node (38 ± 8 vs. 20 ± 8 months, p= 0.2) or liver metastases (51 ± 9 vs. 21 ± 6 months, p = 0.06).ConclusionsCytoreductive surgery combined with HIPEC is feasible and is associated with a reasonable morbidity and mortality. Complete cytoreduction may improve survival in select group of patients with low tumor volume and no organ metastases.
This paper references
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
VJ Verwaal (2003)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
Sugarbaker PH: Peritonectomy procedures
(1995)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)
10.1053/EJSO.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
A. Tentes (2003)
10.1016/S1055-3207(03)00050-4
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.
K. Link (2003)
10.1111/J.1525-1438.2003.13319.X
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1245/ASO.2003.03.067
Long-Term Survivorship and Quality of Life After Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis
R. McQuellon (2003)
10.1002/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
R. Zang (2000)
10.1007/s10434-999-0790-0
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique
A. D. Stephens (1999)
Age contrasts in incidence, histology , disease stage at diagnosis, and mortality Epithelial ovarian cancer
R Yancik (1993)
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
G. Los (1992)
[Advanced ovarian cancer].
J. Guastalla (1995)
10.1006/GYNO.2001.6404
Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
C. Scarabelli (2001)
10.1007/s10434-999-0727-7
Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
P. Sugarbaker (1999)
10.1002/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U
Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
F. Jänicke (1992)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
P. Sugarbaker (2003)
10.1002/CNCR.2820710205
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
R. Yancik (1993)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
10.1200/JCO.1999.17.3.767
Natural history of stage IV epithelial ovarian cancer.
H. Bonnefoi (1999)
10.1097/00001622-200209000-00008
Management of recurrent ovarian cancer: evidence-based decisions.
E. Salom (2002)
10.1177/030089160108700302
Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study
M. Deraco (2001)
10.1053/EJSO.2000.1095
Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma.
P. Piso (2001)
Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using the Coliseum technique
AD Stephens (2000)
10.1007/978-1-4613-1245-1_8
Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer.
P. Sugarbaker (1996)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1056/NEJM199612263352603
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D. Alberts (1996)



This paper is referenced by
10.1245/s10434-009-0484-7
Risk Factors for Massive Blood Transfusion in Cytoreductive Surgery: A Multivariate Analysis of 243 Procedures
A. Saxena (2009)
10.1016/J.JCHIRV.2014.06.003
La chimiohyperthermie intrapéritonéale (CHIP) dans les cancers ovariens
Naoual Bakrin (2014)
10.1002/JSO.20837
Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.
A. Capone (2007)
10.1002/jso.21326
Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Bijan N Moradi (2009)
10.1002/jso.25939
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve.
Charles C Vining (2020)
10.1016/j.jviscsurg.2014.07.005
Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
N. Bakrin (2014)
10.1007/2-287-30921-7_25
La chimiothérapie intrapéritonéale avec hyperthermie
O. Gléhen (2006)
A study on changes and clinical significance of blood glucose, blood lipid and inflammation in patients with ovarian cancer.
Guang-hu Li (2019)
10.1097/SLA.0b013e318255486a
Progression Following Neoadjuvant Systemic Chemotherapy May Not Be a Contraindication to a Curative Approach for Colorectal Carcinomatosis
G. Passot (2012)
10.1007/978-1-4939-1423-4_21
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Reese W Randle (2015)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1007/s00384-006-0246-y
Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model
J. O. Pelz (2006)
10.1007/s11095-020-02818-8
Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy
Sonia Alavi (2020)
10.1016/j.ejso.2015.08.172
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Y. R. Huo (2015)
10.1177/030089161009600306
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
Antonios-Apostolos K Tentes (2010)
10.1007/S12094-007-0118-0
Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals
F. C. Muñoz-Casares (2007)
10.1016/j.gyobfe.2011.11.002
[HIPEC and ovarian carcinoma: base judgment on evidence].
Naoual Bakrin (2012)
Chimio-hyperthermie intrapéritonéale (CHIP) et cancer de l'ovaire: où en sommes-nous?
Gwenael Ferron (2013)
10.1080/02656736.2017.1278631
Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre
A. Arjona-Sánchez (2017)
10.1684/bdc.2010.1063
Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
N. Carrabin (2010)
10.1016/j.soc.2012.07.007
Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.
C. William Helm (2012)
10.1111/j.1471-0528.2011.03207.x
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi‐institutional study
M. Deraco (2012)
10.1002/jso.21083
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.
C. Helm (2008)
10.5152/UCD.2016.3250
Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model.
A. Kurt (2016)
Quimioterapia intraperitoneal hipertérmica con técnica cerrada y sistema de recirculación de CO2 para el tratamiento de carcinomatosis peritoneal
S. S. García (2014)
10.1007/s00423-014-1207-5
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience
I. Koenigsrainer (2014)
10.1186/1477-7819-7-5
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
G. Glockzin (2009)
10.1007/978-1-59745-195-6_9
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer: Experience in France
O. Glehen (2007)
10.1186/1754-9493-6-12
Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients
R. Warschkow (2012)
10.1186/1756-9966-30-4
Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis
O. Facy (2011)
10.2486/indhealth.2014-0025
Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC)
A. Villa (2015)
10.1016/J.YGYNO.2007.03.019
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
J. H. Bae (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar